Overview

Lamotrigine and Bupropion for Meniere's Disease

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled clinical trial to assess whether treatment with lamotrigine and bupropion is more effective than placebo to reduce definitive Meniere's vertigo attacks (DMVA) and dizziness in patients with Meniere's disease. Thirty four participants will be randomized to treatment or placebo groups. Each participant will take part in the trial for 34 weeks, or approximately 9 months.
Phase:
Phase 2
Details
Lead Sponsor:
Dent Neuroscience Research Center
Collaborators:
Cures Within Reach
Dent Family Foundation
Treatments:
Bupropion
Lamotrigine